Patents by Inventor Xiaolan Zhou

Xiaolan Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981999
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 20, 2021
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10913782
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 9, 2021
    Assignee: Biogen MA Inc.
    Inventors: Hq Han, Xiaolan Zhou
  • Publication number: 20200362009
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Application
    Filed: June 8, 2020
    Publication date: November 19, 2020
    Applicant: Biogen MA Inc.
    Inventors: HQ Han, Xiaolan Zhou
  • Publication number: 20200108085
    Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 9, 2020
    Inventors: Huiquan HAN, Christopher Michael HAQQ, Isaac CIECHANOVER, Xiaolan ZHOU, John Zhao-Nian LU
  • Patent number: 10594512
    Abstract: A transport network employs dual homing to an access network to provide connectivity from multiple network switches. Dual homing is a mechanism by which an access network employs pair of switches in the transport network as if it were connecting to a single device. Conventional arrangements for defining multiple paths from a transport network to an access network suffer from the shortcomings of potential routing loops, increased hops to the access network, and inability or inconsistency with forwarding to different types of access networks, and may involve redirecting traffic absent faults in the access network. The dual homed network switches identify the type of access network and perform switching logic corresponding to the access network type to provide comprehensive dual-homed support to the access network independently of the type of transport employed in the access network, and employ redirection only if there is a fault in the access network.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: March 17, 2020
    Assignee: Extreme Networks, Inc.
    Inventors: Srikanth Keesara, Sakthivadivu Saravanaraj, Liming Sun, Xiaolan Zhou
  • Publication number: 20190330307
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Application
    Filed: October 19, 2017
    Publication date: October 31, 2019
    Applicant: BIOGEN MA INC.
    Inventors: HQ HAN, Xiaolan ZHOU
  • Patent number: 10407487
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Publication number: 20190256605
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: March 5, 2019
    Publication date: August 22, 2019
    Applicant: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10266598
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: April 23, 2019
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Publication number: 20180371073
    Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
    Type: Application
    Filed: September 12, 2018
    Publication date: December 27, 2018
    Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Patent number: 10100109
    Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 16, 2018
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Publication number: 20180148491
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Application
    Filed: April 12, 2016
    Publication date: May 31, 2018
    Applicant: AliveGen USA, Inc.
    Inventors: HQ Han, Xiaolan Zhou
  • Publication number: 20180072791
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 15, 2018
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Publication number: 20180069727
    Abstract: A transport network employs dual homing to an access network to provide connectivity from multiple network switches. Dual homing is a mechanism by which an access network employs pair of switches in the transport network as if it were connecting to a single device. Conventional arrangements for defining multiple paths from a transport network to an access network suffer from the shortcomings of potential routing loops, increased hops to the access network, and inability or inconsistency with forwarding to different types of access networks, and may involve redirecting traffic absent faults in the access network. The dual homed network switches identify the type of access network and perform switching logic corresponding to the access network type to provide comprehensive dual-homed support to the access network independently of the type of transport employed in the access network, and employ redirection only if there is a fault in the access network.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 8, 2018
    Inventors: Srikanth Keesara, Sakthivadivu Saravanaraj, Liming Sun, Xiaolan Zhou
  • Patent number: 9813257
    Abstract: A transport network employs dual homing to an access network to provide connectivity from multiple network switches. Dual homing is a mechanism by which an access network employs pair of switches in the transport network as if it were connecting to a single device. Conventional arrangements for defining multiple paths from a transport network to an access network suffer from the shortcomings of potential routing loops, increased hops to the access network, and inability or inconsistency with forwarding to different types of access networks, and may involve redirecting traffic absent faults in the access network. The dual homed network switches identify the type of access network and perform switching logic corresponding to the access network type to provide comprehensive dual-homed support to the access network independently of the type of transport employed in the access network, and employ redirection only if there is a fault in the access network.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: November 7, 2017
    Assignee: Extreme Networks, Inc.
    Inventors: Srikanth Keesara, Sakthivadivu Saravanaraj, Liming Sun, Xiaolan Zhou
  • Patent number: 9809638
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: November 7, 2017
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Publication number: 20170107288
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: August 25, 2016
    Publication date: April 20, 2017
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 9610327
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 4, 2017
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Huiquan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Publication number: 20170073408
    Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
    Type: Application
    Filed: November 8, 2016
    Publication date: March 16, 2017
    Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Patent number: 9453080
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 27, 2016
    Assignee: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai